Giant cell tumor of the bone: Both common and rare clinical aspects. Single institute experience

Giant cell tumor of the bone: Both common and rare clinical aspects. Single institute experience | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Giant cell tumor of the bone: Both common and rare clinical aspects. Single institute experience Akif Mirioglu, Kaan Ali Dalkir, Veli Can Kiran, Hakki Can Olke, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4087425/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective Giant cell tumor of the bone remains one of the popular subjects for its biologically and clinically unpredictable behaviors. This paper presents the long-term outcomes, common and also rare clinical features of the patients with giant cell tumors of the bone. Methods Sixty-eight patients were included in the study between January 1996 and December 2022. Demographic data of the patients were extracted from the hospital database. The radiological assessment was conducted using the Picture Archive Communication System. Information on local adjuvants, filling material of the residual space, systemic administration of Denosumab, and presence of metastasis and local recurrences were enrolled from the patient files. The tumors were classified according to Campanacci classification. Results The most frequent site for the tumor was the knee (59.3%). Among the tumors 22.1% were grade-1, 39.7% were grade-2 and 38.2% were grade-3. The mean tumor volume was 182.8 cm 3 . Sixteen (23.5%) patients had received Denosumab as a systemic treatment. Fifty-five patients were treated with curettage, twelve with resection, and one with amputation. Chemical local adjuvants were used in 42 patients. The tumor bed was filled with cement in 38 patients, bone graft in 12, and remained unfilled in 5 patients. The rate of recurrence was 35.3%. Six patients experienced multiple recurrences. The rate of metastasis was 11.8%, and malignant giant cell tumor of the bone was diagnosed in two (2.9%) patients. Age, gender, tumor grade, size, and location, neo-adjuvant denosumab treatment, the use or type of local adjuvants, and the presence of tumor thrombus were not found to be related to recurrence or metastasis rates; however, marginal resection as initial surgery was found to be significantly related to decreased recurrence rates. Conclusion Metastasis and local recurrence rates were not affected by the preoperative Campanacci grade, neo-adjuvant denosumab administration, type of local adjuvant, filling material, or tumor volume. However, decreased recurrence rate was found to be related to the patients underwent resection. Denosumab Giant cell tumor of the Bone Neoplasm metastasis Neoplasm residual Full Text Additional Declarations No competing interests reported. Supplementary Files supplement1flowchart.tiff Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4087425","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":279392718,"identity":"57df7d43-4493-42fa-a6bc-92b79cbe13f1","order_by":0,"name":"Akif Mirioglu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAUlEQVRIie3PsUrEMBjA8e/j1krWlIo+gRCXwkHFB3GpS2/pgeB6SGIht+heR19CHFsCTpWsmcTiC5yj4GByFdEhraNg/lMS8uNLAEKhv1iEfAMMIoAZh1fujlA0E0TUA0GONxyoW0wQwHpYIZ/tbAnAKCFXSlyas6ddQm5lcnSfXRyslZ2yyk58hD4KUZXsPIrrXibLrqBpd2rJQ7HkPqNx/VKyPGKmtUQqmjaWIFdesq/RTfkkc0d0P07Y8DBLtJAJOmImphx27UDiGqv5tSziO2On5CN/2esWfVW+58eEqNa8yYyketE/b1aZ//tf0fzbJvdc+hlpfnUtFAqF/mEfbhNlWxNIzBgAAAAASUVORK5CYII=","orcid":"","institution":"Cukurova University","correspondingAuthor":true,"prefix":"","firstName":"Akif","middleName":"","lastName":"Mirioglu","suffix":""},{"id":279392719,"identity":"004b1392-47ba-49e3-863a-022dc834e602","order_by":1,"name":"Kaan Ali Dalkir","email":"","orcid":"","institution":"Kadirli State Hospital","correspondingAuthor":false,"prefix":"","firstName":"Kaan","middleName":"Ali","lastName":"Dalkir","suffix":""},{"id":279392720,"identity":"74b4b507-5feb-491e-bc65-be53851341fb","order_by":2,"name":"Veli Can Kiran","email":"","orcid":"","institution":"Yuregir State Hospital","correspondingAuthor":false,"prefix":"","firstName":"Veli","middleName":"Can","lastName":"Kiran","suffix":""},{"id":279392721,"identity":"5f462dff-2fbb-4c60-8129-1c33e3c2c91a","order_by":3,"name":"Hakki Can Olke","email":"","orcid":"","institution":"Başkent University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hakki","middleName":"Can","lastName":"Olke","suffix":""},{"id":279392722,"identity":"1c7c306a-8f89-45b6-8bf4-baa7c8ed80c9","order_by":4,"name":"Bugra Kundakci","email":"","orcid":"","institution":"Cukurova University","correspondingAuthor":false,"prefix":"","firstName":"Bugra","middleName":"","lastName":"Kundakci","suffix":""},{"id":279392723,"identity":"ddd2cf35-bd23-4ff6-b9c6-ef5ef133576c","order_by":5,"name":"Melih Bagir","email":"","orcid":"","institution":"Cukurova University","correspondingAuthor":false,"prefix":"","firstName":"Melih","middleName":"","lastName":"Bagir","suffix":""},{"id":279392724,"identity":"d06d5ed2-34c4-49b4-946b-235a904f07b4","order_by":6,"name":"Mehmet Ali Deveci","email":"","orcid":"","institution":"Koç University","correspondingAuthor":false,"prefix":"","firstName":"Mehmet","middleName":"Ali","lastName":"Deveci","suffix":""},{"id":279392725,"identity":"5b988848-e293-434e-8d2b-76649eb84a97","order_by":7,"name":"Cenk Ozkan","email":"","orcid":"","institution":"Cukurova University","correspondingAuthor":false,"prefix":"","firstName":"Cenk","middleName":"","lastName":"Ozkan","suffix":""}],"badges":[],"createdAt":"2024-03-12 20:29:42","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4087425/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4087425/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":54196022,"identity":"934bea9b-7a19-4488-96b3-94c7d1ab863e","added_by":"auto","created_at":"2024-04-06 00:52:37","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":804600,"visible":true,"origin":"","legend":"","description":"","filename":"GCTBmanuscriptJOSR.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4087425/v1_covered_153e3fce-2085-447d-8a5d-cd6528a43c05.pdf"},{"id":52795797,"identity":"6998fa75-e51f-480f-8296-0fe10b556e37","added_by":"auto","created_at":"2024-03-15 21:52:34","extension":"tiff","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":2262730,"visible":true,"origin":"","legend":"","description":"","filename":"supplement1flowchart.tiff","url":"https://assets-eu.researchsquare.com/files/rs-4087425/v1/7d8097e20f7b1bcf043f9066.tiff"}],"financialInterests":"No competing interests reported.","formattedTitle":"Giant cell tumor of the bone: Both common and rare clinical aspects. Single institute experience","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Denosumab, Giant cell tumor of the Bone, Neoplasm metastasis, Neoplasm, residual","lastPublishedDoi":"10.21203/rs.3.rs-4087425/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4087425/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cb\u003eObjective\u003c/b\u003e\u003c/p\u003e \u003cp\u003eGiant cell tumor of the bone remains one of the popular subjects for its biologically and clinically unpredictable behaviors. This paper presents the long-term outcomes, common and also rare clinical features of the patients with giant cell tumors of the bone.\u003c/p\u003e\u003cp\u003e\u003cb\u003eMethods\u003c/b\u003e\u003c/p\u003e \u003cp\u003eSixty-eight patients were included in the study between January 1996 and December 2022. Demographic data of the patients were extracted from the hospital database. The radiological assessment was conducted using the Picture Archive Communication System. Information on local adjuvants, filling material of the residual space, systemic administration of Denosumab, and presence of metastasis and local recurrences were enrolled from the patient files. The tumors were classified according to Campanacci classification.\u003c/p\u003e\u003cp\u003e\u003cb\u003eResults\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThe most frequent site for the tumor was the knee (59.3%). Among the tumors 22.1% were grade-1, 39.7% were grade-2 and 38.2% were grade-3. The mean tumor volume was 182.8 cm\u003csup\u003e3\u003c/sup\u003e. Sixteen (23.5%) patients had received Denosumab as a systemic treatment. Fifty-five patients were treated with curettage, twelve with resection, and one with amputation. Chemical local adjuvants were used in 42 patients. The tumor bed was filled with cement in 38 patients, bone graft in 12, and remained unfilled in 5 patients. The rate of recurrence was 35.3%. Six patients experienced multiple recurrences. The rate of metastasis was 11.8%, and malignant giant cell tumor of the bone was diagnosed in two (2.9%) patients. Age, gender, tumor grade, size, and location, neo-adjuvant denosumab treatment, the use or type of local adjuvants, and the presence of tumor thrombus were not found to be related to recurrence or metastasis rates; however, marginal resection as initial surgery was found to be significantly related to decreased recurrence rates.\u003c/p\u003e\u003cp\u003e\u003cb\u003eConclusion\u003c/b\u003e\u003c/p\u003e \u003cp\u003eMetastasis and local recurrence rates were not affected by the preoperative Campanacci grade, neo-adjuvant denosumab administration, type of local adjuvant, filling material, or tumor volume. However, decreased recurrence rate was found to be related to the patients underwent resection.\u003c/p\u003e","manuscriptTitle":"Giant cell tumor of the bone: Both common and rare clinical aspects. Single institute experience","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-03-15 21:52:29","doi":"10.21203/rs.3.rs-4087425/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"084c55b2-f046-4cda-9e0c-009baea0c9f5","owner":[],"postedDate":"March 15th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-04-06T00:44:24+00:00","versionOfRecord":[],"versionCreatedAt":"2024-03-15 21:52:29","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4087425","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4087425","identity":"rs-4087425","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}